NO20062930L - Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779 - Google Patents

Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779

Info

Publication number
NO20062930L
NO20062930L NO20062930A NO20062930A NO20062930L NO 20062930 L NO20062930 L NO 20062930L NO 20062930 A NO20062930 A NO 20062930A NO 20062930 A NO20062930 A NO 20062930A NO 20062930 L NO20062930 L NO 20062930L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
directly compressible
oral administration
compressible pharmaceutical
directly
Prior art date
Application number
NO20062930A
Other languages
English (en)
Inventor
Muhammad Ashraf
Eric J Benjamin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20062930L publication Critical patent/NO20062930L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Det beskrives mikronisert CCl-779. Denne direkte pressbare rapamycin 42-ester med 3-hydroksy-2-(hydroksymetyl)-2-metylpropionsyre fører til en lettvint og effektiv fremgangsmåte for å avlevere terapeutiske nivåer av CCl-779 til en pasient.
NO20062930A 2004-01-08 2006-06-22 Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779 NO20062930L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08
PCT/US2004/042178 WO2005070393A2 (en) 2004-01-08 2004-12-14 Directly compressible pharmaceutical composition of the rapamycin ester cci-779

Publications (1)

Publication Number Publication Date
NO20062930L true NO20062930L (no) 2006-10-02

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062930A NO20062930L (no) 2004-01-08 2006-06-22 Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779

Country Status (31)

Country Link
US (1) US20050152983A1 (no)
EP (1) EP1701698B1 (no)
JP (1) JP2007517879A (no)
KR (1) KR20060130162A (no)
CN (1) CN1921861A (no)
AR (1) AR047180A1 (no)
AT (1) ATE383859T1 (no)
AU (1) AU2004314213A1 (no)
BR (1) BRPI0418373A (no)
CA (1) CA2552595A1 (no)
CR (1) CR8491A (no)
CY (1) CY1107373T1 (no)
DE (1) DE602004011398T2 (no)
DK (1) DK1701698T3 (no)
EC (1) ECSP066757A (no)
ES (1) ES2298861T3 (no)
GT (1) GT200500003A (no)
HK (1) HK1090308A1 (no)
HN (1) HN2005000005A (no)
IL (1) IL176519A0 (no)
MX (1) MXPA06007829A (no)
NO (1) NO20062930L (no)
PA (1) PA8621201A1 (no)
PE (1) PE20050683A1 (no)
PL (1) PL1701698T3 (no)
PT (1) PT1701698E (no)
RU (1) RU2006122517A (no)
TW (1) TW200526213A (no)
UA (1) UA84903C2 (no)
WO (1) WO2005070393A2 (no)
ZA (1) ZA200605631B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660081A1 (en) 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
CA2562952A1 (en) * 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
MXPA06012404A (es) * 2004-04-27 2007-01-17 Wyeth Corp Marcado de rapamicina usando metilasas especificas de rapamicina.
EP1855656A2 (en) * 2005-02-15 2007-11-21 Wyeth Orally bioavailable cci-779 tablet formulations
EP1962839A4 (en) 2005-11-14 2010-08-25 Ariad Pharma Inc ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
US9364502B2 (en) * 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
CN110354132A (zh) 2012-06-04 2019-10-22 药品循环有限责任公司 布鲁顿酪氨酸激酶抑制剂的晶形
KR20150032340A (ko) 2012-07-24 2015-03-25 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
TW202315634A (zh) 2015-03-03 2023-04-16 美商製藥公司 布魯東氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶抑制劑之醫藥調配物
EP3345601A4 (en) * 2015-09-03 2019-05-15 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION CONTAINING RAPAMYCIN OR A DERIVATIVE THEREOF
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
KR100542816B1 (ko) * 1996-08-22 2006-01-11 알티피 파마 코포레이션 수불용성 물질의 미립자를 포함하는 조성물 및 이것의 제조 방법
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
DK1635830T3 (da) * 2002-09-17 2009-02-23 Wyeth Corp Granulatformulering af rapamycinesteren CCI-779
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
SG144165A1 (en) * 2003-07-25 2008-07-29 Wyeth Corp Cci-779 lyophilized formulations
MXPA06000951A (es) * 2003-08-07 2006-03-30 Wyeth Corp Sintesis regioselectiva de cci-779.
EP1660081A1 (en) * 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
EP1855656A2 (en) * 2005-02-15 2007-11-21 Wyeth Orally bioavailable cci-779 tablet formulations

Also Published As

Publication number Publication date
ECSP066757A (es) 2006-11-16
WO2005070393A3 (en) 2006-09-28
GT200500003A (es) 2005-08-18
WO2005070393A2 (en) 2005-08-04
DK1701698T3 (da) 2008-05-05
EP1701698B1 (en) 2008-01-16
PT1701698E (pt) 2008-03-27
MXPA06007829A (es) 2006-09-01
CR8491A (es) 2008-08-21
ZA200605631B (en) 2010-01-27
EP1701698A2 (en) 2006-09-20
US20050152983A1 (en) 2005-07-14
HK1090308A1 (en) 2006-12-22
BRPI0418373A (pt) 2007-05-22
CA2552595A1 (en) 2005-08-04
CN1921861A (zh) 2007-02-28
RU2006122517A (ru) 2008-02-20
JP2007517879A (ja) 2007-07-05
UA84903C2 (ru) 2008-12-10
PE20050683A1 (es) 2005-11-04
TW200526213A (en) 2005-08-16
ATE383859T1 (de) 2008-02-15
HN2005000005A (es) 2009-04-17
PL1701698T3 (pl) 2008-03-31
IL176519A0 (en) 2006-10-05
DE602004011398D1 (de) 2008-03-06
AU2004314213A1 (en) 2005-08-04
KR20060130162A (ko) 2006-12-18
DE602004011398T2 (de) 2009-01-15
AR047180A1 (es) 2006-01-11
CY1107373T1 (el) 2012-12-19
ES2298861T3 (es) 2008-05-16
PA8621201A1 (es) 2005-12-23

Similar Documents

Publication Publication Date Title
NO20062930L (no) Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779
ES2729679T3 (es) Derivados de morfinano para el tratamiento de la sobredosis de fármacos
NO20073786L (no) Oralt biotilgjengelige CCI-779-formuleringer
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
DK1725233T3 (da) Farmaceutisk sammensætning omfattende SNS-595 og anvendelse deraf
EP2392322A3 (en) Dosing regimes for trans-clomiphene
NO20065152L (no) Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav
MX2009010268A (es) Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.
AR063782A1 (es) Parche y metodo transdermico para emesis
DE602005021115D1 (de) Verfahren und zusammensetzungen zur oralen fts-abgabe
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
DE60107399D1 (de) Pharmazeutische zusammensetzung mit gesteuerter freigabe enthaltend midodrin und/oder desglymidodrin
ATE513845T1 (de) Peptidsubstanz mit immunogeroprotektiver wirkung, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung
RU2005131578A (ru) Аплидин для лечения множественной миеломы
GEP201606538B (en) Preoperative treatment of post operative pain
Saldanha et al. Histologic evaluation of the effect of nicotine administration on bone regeneration: a study in dogs
BRPI0405520A (pt) novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação
CA2425445A1 (en) Tetrapeptide stimulating functional activity of hepatocytes, pharmacological substance on its basis and the method of its application
BR0307451A (pt) Composição pediátrica oral de trimetobenzamida
RU2531941C1 (ru) Способ профилактики и лечения инфекционных процессов при хирургических стоматологических вмешательствах
RU2003134216A (ru) Способ лечения остеохондроза позвоночника короткими интенсивными курсами
UA40736U (en) METHOD FOR TREATMENT OF VERTEBROGENIUOS radiculopathy
SASAKI et al. Effusion level of exodontia wound after oral administration of cefdinir (CFDN)
UA38381A (uk) Спосіб комплексної терапії депресивно-параноїдного синдрому у хворих шизофренією
UA50497A (uk) Спосіб лікування бронхіальної астми

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application